

=> d his

(FILE 'HOME' ENTERED AT 14:52:14 ON 14 MAR 2000)

FILE 'REGISTRY' ENTERED AT 14:52:29 ON 14 MAR 2000
ACT BORS2/Q

L1

STR

ACT BORIN237P/A

L2

SCR 1166 AND 1705 AND 1996 AND 2014

L3

STR

L4

451 SEA FILE=REGISTRY SSS FUL L3 AND L2

L5

STR L3

L6

0 S L5 SSS SAM SUB=L4

L7

STR L***

L8

10 S L7

L9

10 S L7 SSS SAM SUB=L4

L10

STR L7

L11

6 S L10 SSS SAM SUB=L4

L12

152 S L10 SSS FUL SUB=L4

152 cpds - for dihydroxy + 0-R

FILE 'CAPLUS' ENTERED AT 15:05:31 ON 14 MAR 2000

L13

14 S L12

FILE 'REGISTRY' ENTERED AT 15:09:16 ON 14 MAR 2000

L14

STR L10

L15

0 S L14 SSS SAM SUB=L12

L16

5 S L14 SSS FUL SUB=L12

5 cpds

FILE 'CAPLUS' ENTERED AT 15:12:24 ON 14 MAR 2000

L17

3 S L16

L18

11 S L13 NOT L17

*3 cites w/ dihydroxy R₀**11 cites w/*

FILE 'CAOLD' ENTERED AT 15:18:22 ON 14 MAR 2000

L19

0 S L12

no cite

FILE 'BEILSTEIN' ENTERED AT 15:18:47 ON 14 MAR 2000

L20

0 S L14 FULL

no cite

FILE 'USPATFULL' ENTERED AT 15:19:21 ON 14 MAR 2000

L21

2 S L16

L22

2 S L12

L23

0 S L21 NOT L22

2 cites for dihydroxy

FILE 'MARPAT' ENTERED AT 15:22:22 ON 14 MAR 2000

L24

7 S L14 FULL

7 cites

FILE 'USPATFULL' ENTERED AT 15:24:07 ON 14 MAR 2000

L25

SET SMARTSELECT ON

L26

SEL L21 1- PN 5 2 TERMS

L27

SET SMARTSELECT OFF

FILE 'MARPAT' ENTERED AT 15:24:24 ON 14 MAR 2000

L27

0 S L26



BORIN 09/308,237

=> d que 113

L2
L3

SCR 1166 AND 1705 AND 1996 AND 2014
STR


→ 0 > 15

6 C-OH

6 or more N

parent structure

one
oxygen
can be bonded
to anything



NODE ATTRIBUTES:

NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
CONNECT	IS E1	RC	AT 24
CONNECT	IS E1	RC	AT 25
CONNECT	IS E1	RC	AT 28
CONNECT	IS E1	RC	AT 29
CONNECT	IS E1	RC	AT 30
CONNECT	IS E1	RC	AT 31
CONNECT	IS E1	RC	AT 50
DEFAULT	MLEVEL	IS	ATOM
GGCAT	IS	UNS	AT 48
DEFAULT	ECLEVEL	IS	LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE

L4 451 SEA FILE=REGISTRY SSS FUL L3 AND L2
L10 STR

R = ring


RC = ring or chain

451 cpds

2 open oxygens

BORIN 09/308,237

substructure 1



Page 1-A

7

Page 2-A

NODE ATTRIBUTES:

NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 13
NSPEC IS R AT 14
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 25
CONNECT IS E1 RC AT 28
CONNECT IS E1 RC AT 29
CONNECT IS E1 RC AT 30
CONNECT IS E1 RC AT 31
CONNECT IS E1 RC AT 50
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 48
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 45

STEREO ATTRIBUTES: NONE


L12 152 SEA FILE=REGISTRY SUB=L4 SSS FUL L10
L13 14 SEA FILE=CAPLUS L12

152 cpds

=> d que 116

L2 SCR 1166 AND 1705 AND 1996 AND 2014
 L3 STR

same parent as on p. 2



NODE ATTRIBUTES:


NSPEC IS R AT 8
 NSPEC IS R AT 9
 NSPEC IS R AT 13
 NSPEC IS R AT 14
 CONNECT IS E1 RC AT 24
 CONNECT IS E1 RC AT 25
 CONNECT IS E1 RC AT 28
 CONNECT IS E1 RC AT 29
 CONNECT IS E1 RC AT 30
 CONNECT IS E1 RC AT 31
 CONNECT IS E1 RC AT 50
 DEFAULT MLEVEL IS ATOM
 GGAT IS UNS AT 48
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE

L4 451 SEA FILE=REGISTRY SSS FUL L3 AND L2
 L10 STR



same as substructure 1
on p 3

Page 1-A

O
50

Page 2-A

NODE ATTRIBUTES:


NSPEC IS R AT 8
 NSPEC IS R AT 9
 NSPEC IS R AT 13
 NSPEC IS R AT 14
 CONNECT IS E1 RC AT 24
 CONNECT IS E1 RC AT 25
 CONNECT IS E1 RC AT 28
 CONNECT IS E1 RC AT 29
 CONNECT IS E1 RC AT 30
 CONNECT IS E1 RC AT 31
 CONNECT IS E1 RC AT 50
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY UNS AT 48
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 45


STEREO ATTRIBUTES: NONE

L12 152 SEA FILE=REGISTRY SUB=L4 SSS FUL L10
 L14 STR



Substructure 2

same as substr 2
except the oxygens
at 44; 51 can both
have a connectivity
of 1 (they can only
be bonded to 1C) they
other can be bonded to
H or nothing



Page 1-A

d
50

Page 2-A

NODE ATTRIBUTES:

```

NSPEC  IS R   AT   8
NSPEC  IS R   AT   9
NSPEC  IS R   AT  13
NSPEC  IS R   AT  14
CONNECT IS E1  RC AT 24
CONNECT IS E1  RC AT 25
CONNECT IS E1  RC AT 28
CONNECT IS E1  RC AT 29
CONNECT IS E1  RC AT 30
CONNECT IS E1  RC AT 31
CONNECT IS E1  RC AT 44
CONNECT IS E1  RC AT 50
CONNECT IS E1  RC AT 51
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS AT 48
DEFAULT ECLEVEL IS LIMITED
  
```

GRAPH ATTRIBUTES:

```

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 45
  
```

STEREO ATTRIBUTES: NONE

L16 5 SEA FILE=REGISTRY SUB=L12 SSS FUL L14

5 cpds

=> d bib abs hitstr 121 1

L21 ANSWER 1 OF 2 USPTFULL
 AN 971112576 USPTFULL
 TI Polypeptide compound and a process for preparation thereof
 IN Ohki, Hidenori, Ikeda, Japan
 Tomishima, Masaki, Minoo, Japan
 Yamada, Akira, Fujitara, Japan
 Takasugi, Hisashi, Sakai, Japan
 FUJIOAWA Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
 PA US 5693750 19971202
 PI US 1996-675212 / 19960703 (8)
 RLI Division of Sec. No. US 1994-242854, filed on 16 May 1994, now patented,
 Pat. No. US 5568446
 PRAI GB 1993-10091 19930517
 GB 1993-25269 19931210

DT UTILITY
 EXNAM Primary Examiner: Davenport, Avis M.; Assistant Examiner: Harle,
 Jennifer

LREP Obion, Spivak, McClelland, Maier & Neustadt, P.C.

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1307

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for preparing a polypeptide compound having antimicrobial activities of the following general formula: ##STR1## wherein R.sup.1 is hydrogen

R.sup.2 is acyl group,

R.sup.3 is hydroxy or acyloxy,

R.sup.4 is hydroxy or hydroxysulfonyloxy,

R.sup.5 is hydrogen or lower alkyl which may have one or more suitable substituent(s), and

R.sup.6 is hydrogen, hydroxy or acyl (lower) alkylthio and

a pharmaceutically acceptable salt thereof.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 165727-74-2P

(intermediate for prepn. of fungicidal cyclic peptide compds.)

RN 165727-74-2 USPTFULL

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-[S]-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)





 $\bullet \text{ Na}$

● Na

IT 165727-69-5 165727-74-2
(reaction in prepn. of fungicidal cyclic peptide compds.)
RN 165727-69-5 USP47FULL
CN Pseudomocandin AO, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxybenzoyl)-L-
ornithine]-4-[(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]- (9C)
(CA INDEX NAME)


(reaction in prepn.
 RN 165727-69-5 USPATEFULL

RN 165727-69-5 USPATFULL
 2, 1-((4R, 5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-


CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-2-oxo-1,2,3,4-tetrahydro-4H-pyrimidin-4-yl]-4-[(2,4-dihydroxyphenyl)]-(S)-4-hydroxy-L-threonine]-(9CI)

(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 165727-74-2 USPATEFULL
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




=> d bib abs hitstr l2l 2

L21 ANSWER 2 OF 2 USPATFULL
 AN 96:99198 USPATFULL
 TI Polypeptide compound and a process for preparation thereof
 IN Ohki, Hidenori, Ikeda, Japan
 Tomishima, Masaki, Minoo, Japan
 Yamada, Akira, Fujieda, Japan
 Takasugi, Hisashi, Sakai, Japan
 Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
 PA US 5569646 19961029
 PI US 1994-242854 19940516 (8)
 AI GB 1993-10091 19930517
 PRAI GB 1993-25269 19931210


DT UTILITY
 EXNAM Primary Examiner: Weimar, Elizabeth C.; Assistant Examiner: Marshall, S.
 G.
 LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
 CLMN Number of Claims: 7
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1305
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A polypeptide compound having antifungal activities of the following
 general formula: ##STR1## wherein R.sup.1 is hydrogen R.sup.2 is acyl
 group,
 R.sup.3 is hydroxy or acyloxy,
 R.sup.4 is hydroxy or hydroxysulfonyloxy,
 R.sup.4 is hydrogen or lower alkyl which may have one or more suitable
 substituent(s), and
 R.sup.6 is hydrogen, hydroxy or acyl (lower) alkylthio and a
 pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 165727-74-2P
 (intermediate for prepn. of fungicidal cyclic peptide compds.)
 RN 165727-74-2 USPATFULL
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-
 ornithine]-4-{4-[(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-
 (carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 165727-69-5 165727-74-2
 (reaction in prepn. of fungicidal cyclic peptide compds.)
 RN 165727-69-5 USPATEFULL
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-
 ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 165727-74-2 USPATEFULL
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib ab qhit 124 1

L24 ANSWER 1 OF 7 MARPAT COPYRIGHT 2000 ACS

AN 131:144853 MARPAT

TI Cyclic hexapeptides having antimicrobial activity

IN Ohki, Hidenori; Murano, Kenji; Tojo, Takashi; Shiraiishi, Nobuyuki;
Matsuya, Takahiro; Matsuda, Hiroshi; Mizuno, Hiroaki; Barrett, David;
Matsuda, Keiji; Kawabata, Kohji

PA Fujisawa Pharmaceutical Co., Ltd., Japan; et al.

SO PCT Int. Appl., 470 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO-9940108	A1	19990812	WO-1999-JP538	19990205
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9322998	A1	19990823	AU 1999-22998	19990205
FRAI	AU 1998-1728		19980209		
	AU 1998-3138		19980423		
	WO 1999-JP538		19990205		

AB Polypeptides I [R1 = H, (un)substituted arylaminoalkanoyle, acryl, arylalkanoyle, or alkanoyl, amino protective group, heptylnaphthyl, hexyl-naphthyl; R2 = H, OH; R3 = OH, hydroxyalkoxy, alkoxy; R4 = OH, alkoxy] or their salts were prepd. as antimicrobial activities (esp., antifungal activities). Thus, cyclic peptide II, prepd. via N-acylation using 4-[5-[4-(6-methoxyhexyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoic acid benzotriazol-1-yl ester, showed MIC 0.0625 .mu.g/mL for inhibition of *Candida albicans*.

MSTR 3



G1 = 60

HN—G2
60

SEARCHED BY SUSAN HANLEY 305-4053

Page 1

BORIN 09/308,237


G2 = COpH (SR G11)
G9 - OH
G10 = OH
DER: or salts
MPL: claim 6

=> d bib ab qhit 124 2

L24 ANSWER 2 OF 7 MARPAT COPYRIGHT 2000 ACS
 AN 131:45105 MARPAT
 TI Preparation of Echinocandin B derivatives as antifungal agents
 IN Courtin, Olivier; Fauveau, Patrick; Marquis, Astrid; Melon Manguer,
 Dominique; Michel, Jean-Marc; Schio, Laurent
 PA Hoechst Marion Roussel, Fr.
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9529716	A1	19990617	WO 1998-FR2671	19981209
W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2772028	A1	19990611	FR 1997-15628	19971210
AU 9915659	A1	19990628	AU 1999-15659	19981209
FRAI FR 1997-15628		19971210		
FR 1998-13361		19981026		
WO 1998-FR2671		19981209		
AB	The title compds. [R1, R2 = H, OH, (substituted) alkyl, NR1 forms with the carbon bearing NR1R2 a double bond and R2 = ME; M = O, NH, alkylamino; P = H, (substituted) alkyl; R3 = H, OH, CH3; R4 = H, OH; R = linear or branched chain up to 30 carbon atoms optionally substituted with heteroatoms, aryls or heterocycles; T = H, CH3, CH2CONH2, CH2C.tplbond.N, (CH2)2NH2; Y = H, OH, halogen; W = H, OH; Z = H, CH3] were prep'd. as antifungal agents (no data given). For example, 1-[(4R,5R)-4,5-dihydroxy-N2-(12-methyltetradecanoyl)-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B was treated with trimethylsilyl iodide and sodium thiosulfate in succession to give the intermediate 1-[N2-(12-methyltetradecanoyl)-4-oxo-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B in 62% yield. This intermediate, when treated with 2-(dimethylamino)ethylamine, gave the final product I [NR1R2 = N(CH2CH2NMe2), R = CO(CH2)10CH(CH3)CH2CH3, Z = CH3, W = Y = T = H, R3 = CH3, R4 = OH] as a mixt. of isomers, which were, then, sepd. via HPLC.			

MSTR 4




G16 = 146

$\text{C}_{146}(\text{O})\text{G23}$

G20 = OH

G21 = OH

G23 = 126



DER: or salts

MPL: claim 22

NTE: additional heteroatom interruptions at alkyl in G16 also claimed

=> d bib ab qhit 124 3

L24 ANSWER 3 OF 7 MAREPAT COPYRIGHT 2000 ACS

AN 129:54604 MAREPAT

TI Cyclohexapeptides having antimicrobial activity

IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi

FA Fujisawa Pharmaceutical Co., Ltd., Japan; Ohki, Hidenori; Tomishima,

Masaki; Yamada, Akira; Takasugi, Hisashi

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PT	WO-9823637	A1	19980604	WO-1997-JP4193	19971118
	W:	CA, CN, JP, KR, US			
	RW:	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	EP	941236 A1	19990915	EP 1997-912494	19971118
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
FRAI	AU 1996-3814		19961125		
	WO 1997-JP4193		19971118		
AB	Polypeptide compds. I [R1 = (un)substituted aroyl or alkanoyl; R2 = OH, HO3SO, alkoxy] or their salts were prepd. as antimicrobial agents. Thus, I [R1 = 4-[4-(4-hexyloxyphenyl)piperazin-1-yl]benzoyl, R2 = NaOSO2O] was prepd. by treating I [R1 = H, R2 = NaOSO2O] with 1-[4-[4-(4-hexyloxyphenyl)piperazin-1-yl]benzoyloxy]benzotriazole for 8 h in DMF contg. diisopropylethylamine.				

MSTR 1

G28-G1


G1 = 66

C(O)G2-G3
66 67

G2 = phenylene

G17 = OH

G28 = 64


DER: and salts or reactive derivatives
MPL: claim 1

SEARCHED BY SUSAN HANLEY 305-4053

Page 5

BORIN 09/308,237

NTE: also incorporates claim 10, structure III



G1 = 66

 C(O)-G8
 G6

G2 = OH

G3 = OH

G7 = OH

G8 = Ph (SO (1-3) G11)

DEB: ~~DEB~~

MEL: claim 6


=> d bib ab qhit 124 5

L24 ANSWER 5 OF 7 MARPAT COPYRIGHT 2000 ACS
 AN 123:112725 MARPAT
 TI preparation of polypeptides as antimicrobials
 FA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 47 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06192292	A2	19940712	JP 1993-248668	19930909
PRAI	GB 1992-19068		19920909		

AB Title compds. I [R1 = OH, alkoxy; R2 = OH; R3 = acyl; R4, R5 = OH; R6 = OH, alkanoyloxy; (un)protected carboxyalkoxy; R7 = OH, hydroxysulfonyloxy, (un)protected carboxyalkoxy; R8 = H, (un)substituted alkyl; R1R2 or R3R4 = Q; R9, R10 = H, alkyl; with provisos] and their salts are prepd. Over 20 I were prepd. with data; however, no specific exptl. procedures are given for the prepn. of individual compds. I [R1 = R2 = R4 = R5 = R6 = R7 = R8 = OH, R3 = 6-(octyloxy)-2-naphthoyl, R8 = H] (also prepd.) had an IC50 of 0.2 .mu.g/mL against Candida albicans.


MSTR 1



G1 = OH
 G2 = OH
 G3 = 84

84 C(O)G13

G4 = OH
 G5 = OH
 G6 = OH
 G7 = OH
 G13 = 96



DER: and salts
 MPL: claim 1

BORIN 09/308,237

SEARCHED BY SUSAN HANLEY 305-4053

Page 10

=> d did ab qbit 124 6

L24 ANSWER 6 OF 7 MARPAT COPYRIGHT 2000 ACS


AN 122:82078 MARPAT
 T1 Cyclic peptide antifungal agents and process for preparation thereof
 IN Buckhardt, Frederick Joseph; Debono, Manuel; Nissen, Jeffrey Scott;
 Turner, William Wilson, Jr.
 PA Lilly, Eli, and Co., USA
 SO Eur. Pat. Appl., 56 pp.
 CODEN: EPXXDW
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 561639	A1	19930922	EP-1993-302064	19930318
	CA R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2091663	AA	19930920	CA 1993-2091663	19930315
	ZA 9301830	A	19940915	ZA 1993-1830	19930315
	NO 9300948	A	19930920	NO 1993-948	19930316
	BR 9301232	A	19930921	BR 1993-1232	19930318
	HU 63637	A2	19930928	HU 1993-785	19930318
	CN 1080926	A	19940119	CN 1993-103587	19930318
	CN 1036715	B	19971217		
	JP 06056892	A2	19940301	JP 1993-58529	19930318
	AU 9335341	A1	19930923	AU 1993-35341	19930319
	US 5965525	A	19991012	US 1995-449056	19950524
	AU 9665529	A1	19961205	AU 1996-65529	19960909
	AU 689391	B2	19980326		
	US 5925543	A	19990803	US 1997-873480	19970612
FRAI	US 1992-854117		19920319		
	US 1992-992390		19921216		
	US 1993-32228		19930317		
	US 1996-449056		19950524		

AB Title compds. (I; R, R11 = independently H, OH; R1 = H, OH, OSO₃H; R2 = substituted PhCO, biphenyl, naphthoyl, etc.; R7 = R1, phosphonocoxyl; R8 = H, Me, H₂NCOCH₂; R9, R10 = Me, H), were prepd. Thus, I (R = R7 = R11 = OH, R1 = H, R2 = Q1, R8 = R9 = R10 = Me), prepd. by enzymic deacylation and then reacylation of echinocandin B, showed ED₅₀ = 0.84 mg/mL for controlling systemic fungal infections in mice. Several I were effective against *Pneumocystis carinii* in immunosuppressed rats. I in general exhibit oral bioavailability.

MSTR 1



G3 = OH

SEARCHED BY SUSAN HANLEY 305-4053

Page 11

G4 = OH
G5 = OH
G6 = 63

C(O)G7-G8
63

G7 phenylene
DER: or pharmaceutically acceptable non-toxic salts
MPL: claim 2

not he deroe

=> d bib ab qhit 124 7

L24 ANSWER 7 OF 7 MARPAT COPYRIGHT 2000 ACS

AN 118:213544 MARPAT

TI Pharmaceutical composition against *Pneumocystis carinii*

IN Furuta, Takahisa; Iwamoto, Toshiro; Fujie, Akihiko; Nitta, Kumiko;

Tsurumi, Yasuhisa; Shigematsu, Nobuharu; Kasahara, Chiyoshi; Hino,

Motohiro; Okuhara, Masakuni

PA Fujiwara Pharmaceutical Co., Ltd., Japan

SO Eur. Pat. Appl., 69 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 486011	A2	19920520	EP 1991-119421	19911114
	EP 486011	A3	19920715		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05000966	A2	19930108	JP 1991-354117	19911115
	US 1638	H1	19970304	US 1994-311434	19940926
PRAI	US 1990-614125		19901116		
	GB 1990-27152		19901214		
	GB 1991-1552		19910124		
	GB 1991-6822		19910402		
	US 1990-610759		19901108		
AB	US 1991-791926		19911115		
	FR 901379 derivs. I (R1, R2 = H, acyl; R3 = H, OH, O3SOH; R4 = H, carbamoyl; R5, R6 = H, OH) were prepd. Thus, FR 901379 [I, R1 = CO(CH2)14Me, R2 = H, R3 = O3SOH, R4 = CONH2, R5, R6 = OH, II] was isolated from a culture of <i>Coleophoma</i> sp. F-11899 and deacylated with Actinoplanes utahensis to give II (R1 = H). Acylation of II (R1 = H) with 2,4,5-trichloro-2,6-dichloro-4,6-dimethyl-3,5-dinitrobenzoic acid gave II (R1 = COC6H4O(CH2)7Me-4) which at 2 mg/day i.p. in rats showed significant inhibition of <i>P. carinii</i> pneumocysts.				

MSTR 1



G1 = 72

HH- GG
72

G2 = OH
G3 = OH
G5 = OH
G6 = 90

G(O)G22
90

G22 = Ph (SO)
DER: or pharmaceutically acceptable salts
MPL: claim 1
NFE: ~~substitution is restricted~~

=> d bib abs hitstr 117 1

L17 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2000 ACS

AN 1998:388539 CAPLUS

DN 129:54604

TI Cyclohexapeptides having antimicrobial activity

IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi

PA Fujisawa Pharmaceutical Co., Ltd., Japan; Ohki, Hidenori; Tomishima,

Masaki; Yamada, Akira; Takasugi, Hisashi

SO PCT Int. Appl., 115 pp.

CODEN: FIKXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9823637	A1	19980604	WO 1997-JP4193	19971118

W: CA, CN, JP, KR, US
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 EF 941236 A1 19990915 EF 1997-912494 19971118

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI


PRAI AU 1996-3814 19961125

WO 1997-JP4193 19971118

OS MAREPAT 129:54604

GI

*this
case's
WO*



I

AB Polypeptide compds. I [R1 = (un)substituted aroyl or alkanoyl; R2 = OH, HO3SO, alkoxyl] or their salts were prepd. as antimicrobial agents. Thus, I [R1 = 4-[4-(4-hexyloxyphenyl)piperazin-1-yl]benzoyl, R2 = NaOSO2O] was prepd. by treating I [R1 = H, R2 = NaOSO2O] with 1-[4-(4-hexyloxyphenyl)piperazin-1-yl]benzoyloxy]benzotriazole for 8 h in DMF contg. diisopropylethylamine.

IT 208538-75-4 208538-76-5


RL: RCT (Reactant)

(pregn. of cyclohexapeptides having antimicrobial activity)


RN 208538-75-4 CAPLUS

CN Pneumocandin AQ, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-(3,4-dihydroxyphenyl)-4-hydroxy-L-threonine]-5-[(3S)-3-hydroxy-L-glutamine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




*this
case*

RN 208538-76-5 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-
isoxazolyl]benzoyl]-L-proline]-4-[(4S)-4-[3,4-dihydroxyphenyl]-4-hydroxy-
L-threonine]-5-[(3S)-3-hydroxy-L-glutamine], compd. with
N,N-bis(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 208538-75-4
CMF C56 H71 N9 O20

PAGE 1-A



PAGE 2-A



CM 2

CRN 3424-21-3

CMF C9 H21 N



=> d bib abs hitstr l17 2

L17 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2000 ACS
 AN 1995:763519 CAPLUS
 DN 123:228903
 TI Preparation of cyclic peptide compounds as .beta.-1,3-glucan synthase
 inhibitors and antimicrobial agents
 IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
 FA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO Can. Pat. Appl., 85 pp.
 CODEN: CPXKEB
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2123921	AA	19941118	CA 1994-2123921	19940517
	AU 9461994	A1	19941124	AU 1994-61994	19940510
	AU 681119	B2	19970821		
	EP 644199	A1	19950322	EP 1994-107406	19940512
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1100104	A	19950315	CN 1994-105193	19940516
	ZA 9403356	A	19950328	ZA 1994-3356	19940516
	HU 68385	A2	19950628	HU 1994-1515	19940516
	US 5569646	A	19961029	US 1994-242854	19940516
	JP 06340693	A2	19941213	JP 1994-126977	19940517
	US 5693750	A	19971202	US 1996-675212	19960703
PRAI	GB 1993-10091		19930517		
	GB 1993-25269		19931210		
	US 1994-242854		19940516		
OS	MAREPAT 123:228903				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Cyclic peptide compds. [I; R1 = H; R2 = acyl; R3 = OH, acyloxy; R4 = HO, OSO3H; R5 = H or a lower alkyl group which is optionally substituted with a HO, acyl, di(lower)alkylamino or cyclic amino group; R6 = H, OH, or acyl-lower alkylthio] and pharmaceutically acceptable salts thereof, useful as fungicides for the treatment of *Pneumocystis carinii* infection, are prepd. Thus, 0.285 g NaBH3CN was added to a soln. of 1 g I (R1 = R3 = R6 = OH, R2 = Q, R4 = NaO3SO, R5 = H) in CF3CO2H contg. mol. sieves 4A and the resulting mixt. was stirred at ambient temp. for 1 h to give, after chromatog. by an ion-exchange column on DOWEX 50WX4 (Na+-type) and HPLC using a C18.mu. Bondapak resin, column chromatog. on ODS [YMC-gel ODS-RMS-50], and lyophilization, 318 mg I (R1 = R5 = H, R2 = Q, R3 = R6 = OH, R4 = NaO3SO) and 263 mg I (R1 = R5 = R6 = H, R2 = Q, R3 = OH, R4 = NaO3SO). I (R1 = R5 = H, R2 = Q1, R3 = R6 = OH, R4 = NaO3SO) showed IC50 of 0.05 .mu.g/mL against *Candida albicans* YU-1200.

IT 165727-74-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (intermediate for prepn. of fungicidal cyclic peptide compds.)


RN 165727-74-2 CAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)]-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

IT 165727-69-5 165727-74-2


RL: RCT (Reactant)

(reaction in prepn. of fungicidal cyclic peptide compds.)


RN 165727-69-5 CAPLUS

CN Pneumocandin A0, 1-[4R,5R]-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]- (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 165727-74-2 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-[3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)


=> d bib abs hitstr 117 3

LI7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2000 ACS
 AN 1995:716709 CAPLUS
 DN 123:112725
 TI preparation of polypeptides as antimicrobials
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 47 pp.
 CODEN: JXXXXF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06192292	A2	19940712		
PRAI	GB 1992-19068		19920909	JP 1993-248668	19930909
OS	MARPAT-123:112725				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = OH, alkoxy; R2 = OH; R3 = acyl; R4, R5 = OH; R6 = OH, alkanoyloxy; (un)protected carboxyalkoxy; R7 = OH, hydroxysulfonyloxy, (un)protected carboxyalkoxy; R8 = H, (un)substituted alkyl; R1R2 or R3R4 = Q; R9, R10 = H, alkyl; with provisos] and their salts are prepd. Over 20 I were prepd. with data; however, no specific exptl. procedures are given for the prepn. of individual compds. I [R1 = R2 = R4 = R5 = R6 = R7 = R8 = OH, R3 = 6-(octyloxy)-2-naphthoyl, R8 = H] (also prepd.) had an IC50 of 0.2 µg/mL against *Candida albicans*.
 IT 165727-74-2P 165727-80-OP
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of polypeptides as antimicrobials)
 RN 165727-74-2 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)




PAGE 2-A




● Na

RN	165727-80-0	CAPLUS
CN	Pneumocandin A0, 1-([4R,5R]-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-[[dimethylamino)methyl]-threo-3-hydroxy-L-glutamine]- (9CI) (CA INDEX NAME)	

PAGE 1-A



PAGE 2-A



IT 165727-69-5


RL: RCT (Reactant)

(reactant in prepn. of polypeptides as antimicrobials)


RN 165727-69-5 CAPLUS

CN Pneumocandin A0, 1-[4R,5R]-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]- (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A



PAGE 1-A




PAGE 2-A




● Na

RN 235114-39-3 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-N2-[(4'-heptyl[1,1'-biphenyl]-4-yl)carbonyl]-4,5-dihydroxy-L-ornithine]-4-[(4S)-4-hydroxy-4-[(4-hydroxy-3-(sulfooxy)phenyl)-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 235114-41-7 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-N2-[(4'-hexyl[1,1'-biphenyl]-4-yl)carbonyl]-
 4,5-dihydroxy-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-
 (sulfoxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 235114-42-8 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-N2-[4-[4-(4-hexyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxy-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxy-3-(sulfoxy)phenyl)-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 235114-45-1 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[4-[4-(8-methoxyoctyloxy)phenyl]-1-piperazinyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 235114-46-2 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-{4-[4-[(1-methoxyheptyl)oxy]phenyl]-1-piperazinyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 235114-48-4 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-N2-[4-[5-[4-(hexyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-4,5-dihydroxy-L-oronithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

IT 235108-74-4P 235108-75-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 [cyclic hexapeptides having antimicrobial activity]
 RN 235108-74-4 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-N2-[4-[2-(4-butoxyphenyl)imidazo[2,1-b]-1,3,4-thiadiazol-6-yl]benzoyl]-4,5-dihydroxy-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxy-3-(sulfooxy)phenyl)-L-threonine]-, monosodium salt [9CI] (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 235108-75-5 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[2-[4-(pentyloxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-6-yl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr 118 3

L18 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2000 ACS

AN 1999:492332 CAPLUS

DN 131:269425

TI FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity

AU Tomishima, Masaki; Ohki, Hidenori; Yanada, Akira; Takasugi, Hisashi; Maki, Katsuyuki; Tawara, Shuichi; Tanaka, Hirokazu

CS Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co. Ltd., 2-1-6 Kashima Yodogawa-ku, Osaka, 532-8514, Japan

SO J. Antibiot. (1999), 52(7), 674-676

CODEN: JANTAJ; ISSN: 0021-8820

PB Japan Antibiotics Research Association

DT Journal

LA English

AB

The novel water-sol. echinocandin lipopeptide FK463 (I) was prepd. by cycloaddn. reaction to give the key intermediate Me 4-(5-[4-pentyloxyphenyl]isoxazol-3-yl)benzoate (II) followed by II hydrolysis and condensation to yield the activated ester, and acylation of the activated ester with the cyclic peptide nucleus obtained by enzymic cleavage of the natural product FR901379. I exhibited broad-spectrum activity against clin. important pathogens including *Aspergillus* and azole-resistant and -susceptible *Candida* species; it had no activity against *Cryptococcus neoformans*.


IT 208538-73-2P, FK463


RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (synthesis and antifungal activity of the novel water-sol. echinocandin lipopeptide FK463)

RN 208538-73-2 CAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[[4S]-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A






• Na

=> d bib abs hitstr 118 4


L18 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:150173 CAPLUS
 DN 131:13178
 TI FK-463: Antifungal
 AU Fromtling, Robert A.; Castaner, J.
 CS Liaison-International, Merck Research Laboratories, Rahway, NJ,
 07065-0900, USA
 SO Drugs Future (1998), 23(12), 1273-1278
 CODEN: DRFUD4; ISSN: 0377-8282
 BB Prous Science
 DT Journal: General Review
 LA English
 AB A review with 26 refs. FK-463 represents the latest lead in a novel chem. class of echinocandin-like lipopeptide antifungal compds. This agent has potent in-vitro and exptl. in vivo activity against a variety of pathogenic Candida species (yeasts) and A. fumigatus (filamentous fungus). This compd. has favorable exptl. pharmacokinetics and a unique mode of action which makes it active against fungal isolates that are resistant to established antifungal agents particularly the triazole agent fluconazole. This new lead compd. is undergoing extensive preclin. evaluation in Japan to det. whether it may be a candidate for further development as a novel antifungal agent. Single-dose and initial multiple-dose phase I studies in normal human volunteers have been completed with the compd. being generally well tolerated. FK-463 has advanced to phase II clin. trials (26).
 IT 208538-73-2, FK 463
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (FK-463 as echinocandin-like lipopeptide antifungal compd. in humans and lab. animals)
 RN 208538-73-2 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



SEARCHED BY SUSAN HANLEY 305-4053

Page 17



● Na

=> 4 bib abs hitstr 118 5

L18 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2000 ACS

AN 1998:352867 CAPLUS

DN 129:53437

TI Cyclic hexapeptides having antibiotic activity

IN Kanasaki, Ryuichi; Takase, Shigehiro; Hashimoto, Michizane; Hatanaka, Hiroshi; Sakamoto, Kazutoshi; Hashimoto, Seiji; Shiraishi, Nobuyuki; Ohki, Hidenori; Kawabata, Kohji

PA Fujisawa Pharmaceutical Co., Ltd., Japan; Kanasaki, Ryuichi; Takase, Shigehiro; Hashimoto, Michizane; Hatanaka, Hiroshi; Sakamoto, Kazutoshi; Hashimoto, Seiji; Shiraishi, Nobuyuki; Ohki, Hidenori; Kawabata, Kohji

SO PCT Int. Appl., 51 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9822408	Al	19980528	WO 1997-JP4194	19971118
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			EP 1997-912495	19971118
EP 941237	Al	19990915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
PRAI AU 1996-3715		19961119		
WO 1997-JP4194		19971118		
OS MARPAT 129:53437				
GI				



I

AB This invention relates to new polypeptide compds. (I: R1 = H or acyl) or a salt thereof, which have antimicrobial activities (esp., antifungal activities), inhibitory activity on beta-1,3-glucan synthase, to a process for prepn. thereof, to a pharmaceutical compn. comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal. Manuf. of I with Coleophoma sp. F-11899 by aerobic fermn. and chem. synthesis were shown. The physiol. and morphol. characteristics of Coleophoma sp. F-11899 were also given.

IT 208511-84-CP 208511-85-7P 208511-86-8P
208511-88-0P 208511-89-1P

SEARCHED BY SUSAN HANLEY 305-4053

Page 19


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cyclic hexapeptides having antibiotic activity)


RN 208511-84-6 CAPLUS

CN Proline, N2-[4-[4-(4-(hexyloxy)phenyl)-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 208511-85-7 CAPLUS

CN Proline, N2-[4-[5-[4-(4-(hexyloxy)phenyl)-1,3,4-thiadiazol-2-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1 A




PAGE 2-A




● Na

RN 208511-86-8 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-3-(sulfoxy)phenylthreonyl-3-hydroxyglutaminyl-3-hydroxy-, [6.fwdarw.1]-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 208511-88-0 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]ornithylthreonyl-4-hydroxypropyl-4-hydroxy-4-[4-hydroxy-3-(sulfamoyl)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-, (6.fwdarw.1)-lactam, monosodium salt (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN	208511-B9-1	CAPLUS
CN	Proline, 4,5-dihydroxy-N2-[[4'-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxypropyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxylphenyl)threonyl-3-hydroxyglutaminyl-3-hydroxy-, (6.fdwaw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)	

PAGE 1-A



PAGE 2-A




● Na


=> d bib abs hitstr l18 6

L18 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2000 ACS
 AN 1998:47005 CAPLUS
 DN 128:188328
 TI Therapeutic effect of a water-soluble echinocandin compound on
 Pneumocystis pneumonia in animals
 AU Furuta, Takahisa; Muramatsu, Hideyuki; Fujie, Akihiko; Fujihira, Shiro
 CS Dept. Parasitology, Inst. Med. Sci., Univ. Tokyo, Tsuba, Japan
 SO J. Eukaryotic Microbiol. (1997), 44(6), 535
 CODEN: JEMIED; ISSN: 1066-5234
 PB Society of Protozoologists
 DT Journal
 LA English
 AB Recently, it has been reported that a .beta.-1,3 -D-glucan synthesis
 inhibitor has growth inhibitory effects on fungi through inhibiting the
 synthesis of .beta.-1,3-glucan which is present in fungal cell walls. The
 inhibitor is also effective against Pneumocystis carinii infection because
 the cell wall of P. carinii cyst resembles that of the yeast Saccharomyces
 cerevisiae and contains high levels of .beta.-1,3-glucan. Since
 .beta.-1,3-glucan synthesis activity is not present in mammalian cells, it
 was thought that inhibition of the synthesis might be a good target to
 prevent the formation of P. carinii cysts and thus to selectively kill P.
 carinii in infected lung. Generally, however, the lipopeptide compds. so
 far reported as the .beta.-1,3-D - glucan inhibitor are hardly sol. in
 water. This insolv. limits their potential use as parenterally applicable
 agents and is one of the reason why they can not be developed for clin.
 use. We recently found that a strain of Coleophoma empetri F-11899
 produces water-sol. echinocandin analogs, which have strong inhibitory
 effects on the growth of fungi. In this paper, we examd. the therapeutic
 effectiveness of a water-sol. echinocandin analog FRI31535 on Pneumocystis
 pneumonia in immunodeficient animals. The results of this study indicate
 that the compd. is potentially useful for the treatment of Pneumocystis
 pneumonia.
 IT 144371-87-9, FR 131535
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pneumocystis pneumonia inhibition by echinocandin compd. FR131535)
 RN 144371-87-9 CAPLUS
 CN Pneumocandin A0, 1-[[[4R,5R]-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-
 ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-
 (9CI) [CA INDEX NAME]

PAGE 1-A




PAGE 2-A




=> d bib abs hitstr l18 ?

L18 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2000 ACS
 AN 1998:24752 CAPLUS
 DN 128:175816
 TI Therapeutic effects of water-soluble echinocandin compounds on
 Pneumocystis pneumonia in mice
 AU Furuta, Takahisa; Muramatsu, Hideyuki; Fujie, Akihiko; Fujihira, Shiro,
 Abudullah, Noor Rain; Kojima, Somet
 CS Department of Parasitology, The Institute of Medical Science, The
 University of Tokyo, Tokyo, 108, Japan
 SO Antimicrob. Agents Chemother. (1998), 42(1), 37-39
 CODEN: AMACQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English
 AB The therapeutic effectiveness of water-sol. echinocandin compds. obtained
 from *Coleophoma empetri* F-11899, which has a strong inhibitory effect on
 the growth of fungi, was examd. in nude mice with exptl. *Pneumocystis*
 pneumonia. The studies demonstrated the potential usefulness of the
 compds.
 IT 144371-87-9, FR 131535
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (144371879; therapeutic effects of water-sol. echinocandin compds. on
Pneumocystis pneumonia in mice)
 RN 144371-87-9 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-
 ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-
 (9CI) (CA INDEX NAME)

PAGE 1-A





=> d bib abs hitstr 118 8

L18 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1996:462227 CAPLUS
DN 125:115150

TI Cyclic hexapeptides having antibiotic activity
IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
FA Fujisawa Pharmaceutical Co., Ltd., Japan
SO ECT Int. Appl., 273 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9611210	A1	19960418	WO 1995-JP1983	19950929
	W: AU, CA, CN, FI, HU, JP, KR, MX, NO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, FT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2202058	AA	19960418	CA 1995-2202058	19950929
	AU 9535780	A1	19960502	AU 1995-35780	19950929
	AU 696949	B2	19980924		
	EP 788511	A1	19970813	EP 1995-932935	19950929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, FT, SE				
	CN 1168675	A	19971224	CN 1995-196643	19950929
	JP 10507174	T2	19980714	JP 1995-512472	19950929
	JP 2897427	B2	19990531		
	HU 77736	A2	19980728	HU 1998-338	19950929
	JP 10324695	A2	19981208	JP 1998-136756	19950929
	ZA 9508458	A	19960507	ZA 1995-8458	19951006
	BR 9504791	A	19961022	BR 1995-4791	19951006
	FI 9701397	A	19970527	FI 1997-1397	19970404
	NO 9701544	A	19970604	NO 1997-1544	19970404
PRAI	GB 1994-20425		19941007		
	GB 1995-8745		19950428		
	JP 1996-512472		19950929		
	WO 1995-JP1983		19950929		
OS	MAREPAT 125:115150				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The invention relates to new cyclic polypeptide derivs. I [R1 = variety of substituted acyl groups] and their pharmaceutically acceptable salts. The compds. have antimicrobial activities (esp., antifungal activities) and inhibitory activity on .beta.-1,3-glucan synthase (no data), and are useful for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g., P. carinii pneumonia). Examples include 124 compds. I, plus 346 precursor prepn. For instance, reaction of the precursor I.Na [R1 = H] with 1-[6-[(octyloxy)methyl]picolinoyl]benzotriazole 3-oxide in DMF in the presence of DMAP gave title compd. I [R1 = Q1]. In a test against Candida albicans EP-633 in vitro, I [R1 = Q2] had MIC of 0.2 .mu.g/mL.
- IT
- 179165-46-9P 179165-47-0P 179165-53-8P
179165-66-3P 179165-67-4P 179165-68-5P
179165-69-6P 179165-70-9P 179165-80-1P
179165-81-2P 179165-83-4P 179165-84-5P
179165-85-6P 179165-86-7P 179165-87-8P
179165-88-9P 179165-89-0P 179165-92-5P
179165-97-0P 179165-98-1P 179165-99-2P
179166-01-9P 179166-09-7P 179166-10-0P
179166-11-1P 179166-12-2P 179166-13-3P
179166-16-6P 179166-17-7P 179166-18-8P
179166-19-9P 179166-20-2P 179166-34-8P
179166-35-9P 179166-36-0P 179166-38-2P

SEARCHED BY SUSAN HANLEY 305-4053

179166-39-3P 179166-40-6P 179166-41-7P
 179166-42-8P 179166-43-9P 179166-44-0P
 179166-45-1P 179166-46-2P 179166-47-3P
 179166-48-4P 179166-49-5P 179166-50-8P
 179166-53-1P 179166-54-2P 179166-56-4P
 179166-58-6P 179166-60-0P 179166-61-1P
 179166-62-2P 179166-88-2P 179166-89-3P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); DIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of cyclic hexapeptides active against fungi and Pneumocystis carinii)


RN 179165-46-9 CAPLUS
 CN

Prolina, 4,5-dihydroxy-N2-[4-[4-(4-(octyloxy)phenyl)-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Na

SEARCHED BY SUSAN HANLEY 305-4053


Page 30

RN 179165-47-0 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[[4'-[[(8-[[1H-1,2,4-triazol-1-yl]octyl]oxy]]1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxypropyl-3-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-53-8 CAPLUS
 CN Proline, N2-[3,4-bis(pentyleoxy)benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxypropyl-3-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Na


RN 179165-66-3 CAPLUS

CN Proline, N2-[(4'-hexyl[1,1'-biphenyl]-4-yl)carbonyl]-4,5-dihydroxyphenylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxyphenyl)threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Na

RN 179165-67-4 CAPLUS


CN

Proline, N2-[4-[4-[4-(hexyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, (6.6dwar.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-68-5 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[[[4'-[(8-methoxyoctyl)oxy] [1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[(4-hydroxy-3-(sulfoxy)phenyl)threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-69-6 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[[4'-(7-octenyloxy)[1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-3-(sulfoxy)phenylthreonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.1wdaaw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1 A




PAGE 2-A




● Na

RN 179165-70-9 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)




PAGE 2-A




● Na

RN	179165-80-1	CAPLUS
CN	Proline, N2-((4'-heptyl[1,1'-biphenyl]-4-yl)carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxypropyl-4-hydroxy-4-[4-hydroxy-3-sulfohexyl]phenylthreonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) [CA INDEX NAME]	

PAGE 1-A.




PAGE 2-A




● Na

RN 179165-81-2 CAPLUS
 CN Proline, N2-[4-[4-[4-[1,5-dihydro-1-(4-methylpentyl)-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-83-4 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[4-[4-[7-methoxyheptyl]oxy]phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-84-S CAPLUS
 CN Proline, N2-[4-[4-[6-(heptyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1 A




PAGE 2-A




● Na

RN 179165-85-6 CAPLUS
 CN Proline, N2-[4-[4-(4-(heptyloxy)phenyl)-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-86-7 CAFLUS
 CN Proline, 4,5-dihydroxy-N₂-(4-[4-[(4-methylpentyl)oxy]phenyl]-1-piperazinyl)benzoyl)ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-87-8 CAPLUS
 CN Proline, 4,5-dihydroxy-N²-(4-[4-[4-(pentyloxy)phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic [6.fwda.rw.1]-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-88-9 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[[[4'-[[[8-[[1H-tetrazol-1-yl]octyl]oxy][1,1'-biphenyl]-4-yl]]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-(4-hydroxy-3-(sulfoxy)phenyl)threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-89-0 CAPLUS
 CN Proline, N2-[4'-[1,1'-biphenyl-4-yl]carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-92-5 CAPLUS
 CN Proline, N2-[(4'-butoxy[1,1':4',1''-terphenyl]-4-yl)carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[(4-hydroxy-3-sulfamoylphenyl)threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)




PAGE 2-A




● Na

RN	179165-97-0	CAPLUS
CN	Proline, 4,5-dihydroxy-N2-[[4'-[(5-phenoxyphenyl)oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxypropyl-4-hydroxy-4-[4-hydroxy-3-(sulfofeno)phenyl]threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6.fdwarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




● Na

RN 179165-98-1 CAFLUS
 CN Proline, N2-[4-[5-[4-(hexyloxy)phenyl]-1,3,4-oxadiazol-2-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179165-99-2 CAPLUS
 CN Proline, N2-[4-[5-[4-(hexyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, (6,7-diaz-1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-01-9 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(5-pentyloxy)phenyl]-1H-pyrazol-3-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic [6.fwdarw.1]-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Na


RN 179166-09-7 CAPLUS

Proline, 4,5-dihydroxy-N2-[4-[4-[4-(8-methoxyoctyl)oxy]phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, {6.fwdarw.l}-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-10-0 CAPLUS
 CN Froline, 4,5-dihydroxy-N2-[4-[4-[4-(7-octenyloxy)phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxypropyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-11-1 CAPLUS
 CN Proline, N2-[3-fluoro-4-[4-[4-(hexyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-
 dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-
 (sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic
 (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-12-2 CAPLUS
 CN Proline, N2-[3-chloro-4-[4-[4-(hexyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-13-3 CAPLUS
 CN Proline, N2-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-4,5-
 dihydroxyornithylthreonyl-4-hydroxypropyl-4-hydroxy-4-[4-hydroxy-3-
 (sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic
 (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● Na

RN 179166-16-6 CAPLUS
 CN Proline, N2-[4-[4-(4-cyclohexylphenyl)-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-17-7 CAPLUS
 CN Proline, N2-[4-[4-(4-hexylphenyl)-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxyphenyl)threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic [6.Edarw.1]-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-18-8 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[4-(4-phenylcyclohexyl)-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-(4-hydroxy-3-(sulfoxy)phenyl)threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic [6.fwdarw.4]-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-19-9 CAPLUS
 CN Prolina, N2-[4-[1-[4-(hexyloxy)phenyl]-4-piperidinyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-20-2 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-(4-pentylcyclohexyl)benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-34-8 CAPLUS
 CN Proline, N2-[4-[5-[4-(hexyloxy)phenyl]-1H-pyrazol-3-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic [6.fwdarw.1]-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-35-9 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[[4'''-[(6-methoxyhexyl)oxy]]{1,1':4',1''-terphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Na


RN 179166-36-0 CAPLUS

CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-[(8-methoxyoctyl)oxy]phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN	179166-38-2	CAPLUS
CN	Proline, N2-[4-[5-[4-(4-cyclohexylphenyl)-1,3,4-thiadiazol-2-yl]benzoyl]-4,5-dihydroxyornithyl]threonyl-4-hydroxypropyl-4-hydroxy-4-[4-(4-hydroxy-3-(sulfofeno)phenyl)threonyl]-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6.f6dwrw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




● Na

RN 179166-39-3 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[5-[4'-propoxy[1,1'-biphenyl]-4-yl]-1,3,4-oxadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)




PAGE 2-A




● Na

SEARCHED BY SUSAN HANLEY 305-4053

PAGE 1-A




PAGE 2-A




● Na

RN 179166-41-7 CAPLUS
 CN Proline, N2-[4-[3-[4-(hexyloxy)phenyl]-1,2,4-oxadiazol-5-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-42-8 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(octyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.1wdaaw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-43-9 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[5-(4-pentylcyclohexyl)-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-oxo-4-phenylthiophenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.6wdaaw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-44-0 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[3-[4-(pentyloxy)phenyl]-5-
 isoxazolyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-
 3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-,
 cyclic [6.fwdarw.1]-peptide, monosodium salt (9CI) [CA INDEX NAME]

PAGE 1-A



PAGE 2-A



● Na


RN 179166-45-1 CAPLUS

CN
Proline, 4,5-dihydroxy-N2-[4-[5-[4-[(8-methoxyoctyl)oxy]phenyl]-1,3,4-oxadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)


SEARCHED BY SUSAN HANLEY 305-4053

Page 71

PAGE 1-A




PAGE 2-A




● Na

RN 179166-46-2 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[[4'-[(6-phenyl-3-pyridazinyl)oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-47-3 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(octyloxy)phenyl]-1,3,4-oxadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxyphenyl)threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.1w.dar.1)]-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-49-5 CAPLUS
 CN Proline, N2-[[4'-[[8-(2-ethoxyethoxy)octyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[[4-hydroxy-3-[sulfoxy]phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-50-8 CAPLUS
 CN Froleine, 4,5-dihydroxy-N2-[[4'--[[8-oxo-8-(1-piperidinyl)octyl]oxyl[1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Na


RN 179166-53-1 CAPLUS

CN Frosline, 4,5-dihydroxy-N2-[4-[5-(4'-propoxy[1,1'-biphenyl]-4-yl)-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxypropyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-54-2 CAPLUS
 CN Proline, N2-[4-(1-heptyl-1H-pyrazol-4-yl)benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-3-(sulfooxylphenyl)threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-56-4 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[(4'-pentyl[1,1'-biphenyl]-4-yl)carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)


$$\frac{Dh}{Dx} = 1 - h$$


PAGE 2-A


 \bullet Na

RN	179166-58-6	CAPLUS
CN	Proline, 4,5-dihydroxy-N2-[[4'-[[8-[[tetrahydro-2H-pyran-2-yl]oxy]ethoxy]oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxypropyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




● Na

RN 179166-60-0 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4'-[[(6-propoxyhexyl)oxy]1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[(4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Na


RN 179166-61-1 CAPLUS

CN Proline, 4,5-dihydroxy-N2-[[4'-[(5-methoxypentyl)oxy][1,1':4',1''-terphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-62-2 CAPLUS
 CN Erolone, 4,5-dihydroxy-N2-[4-[5-[4-(1-piperidinyl)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-00-2 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxypropyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 179166-89-3 CAPLUS
 CN Proline, 4,5-dihydroxy-N2-[[4'-[[8-[(2H-tetrazol-2-yl)octyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1 A.



PAGE 2-A




● Na

=> d bib abs hitstr l18 9

L18 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2000 ACS
 AN 1994:164908 CAPLUS
 DN 120:164908
 TI Preparation of cyclic peptide derivatives as antibacterial agents
 TN Oki, Hidetoku; Kawabata, Koji; Itane, Kazuo
 PA Fujiwara Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 21 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CWP 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05202096	A2	19930810	JF 1992-291149	19921029
PRAI	GB 1991-23046		19911030		
OS	MAREPAT 120:164908				
GI					



AB N-acetylcyclopeptides (I; M = H; R = C₉-10 (1 or 2 halo-substituted)alkoxy-benzoyl, (un)protected carboxybenzoyl, carboxy-higher alkoxy-benzoyl, lower alkoxyphenyl-benzoyl, hydroxy-higher alkoxyphenyl-benzoyl, lower alkenyloxyphenyl-benzoyl, C₇ alkoxy-naphthoyl, (un)substituted aracylamino-lower alkanoyl, (un)substituted indolyl- or pyrazolyl-lower alkanoyl, steroid-contg. lower alkanoyl) or their salts are prepd. Thus, 0.393 g 4-dimethylaminopyridine was added to a soln. of 2.8 g 6-heptyloxy-2-naphthoic acid N-hydroxysuccinimide ester (prepn. given) and I (M = Na, R = H) in DMF and the soln. was stirred at room temp. for 12 h to give, after ion column chromatog. using Dowex-50Wx4 and column chromatog. using ODS YMC-gel (ODS-AM S-50) (Yamamura Kagaku Kenkyusho Inc., Ltd.), 1.94 g I (M = Na, R = 6-heptyloxy-2-naphthoyl) (II). II showed min. inhibitory concn. of 0.1 .mu.g/mL against Candida albicans FF579. A total of 21 I (M = Na) were prepd.

IT 152868-86-5P 152868-87-6P 152868-88-7P
 152868-89-8P 152868-90-1P 152868-91-2P
 152868-92-3P 152868-93-4P 152868-94-5P
 152868-95-6P 152868-96-7P 152868-97-8P
 152868-98-9P 152868-99-0P


RL: BAC (Biological activity or effector, except adverse); SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

SEARCHED BY SUSAN HANLEY 305-4053


Page 87

(prepn. of, as antibacterial agent)
 RN 152868-86-5 CAPLUS
 CN L-Proline, N2-[4-(decyloxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic [6.fwdarw.1]-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(5CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-87-6 CAPLUS
 CN L-Proline, N2-[4-[(3,7-dimethyloctyl)oxy]benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic [6.fwdarw.1]-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(5CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-88-7 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-[(nonadecafluorononyl)oxy]benzoyl]-
 L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-
 3-(sulfoxyphenyl)-L-threonyl-3-hydroxyglutamyl]-3-hydroxy-4-methyl-,
 cyclic (6.6wdaew.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-89-8 CAPLUS
 CN L-Proline, N2-[4-[(3,7-dimethyloctyl)oxy]-3-fluorobenzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic [6.fwdarw.1]-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-90-1 CAPLUS
 CN L-Proline, N2-[4-[(3,7-dimethyloctyl)oxy]-2,3,5,6-tetrafluorobenzoyl]-
 (4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-
 hydroxy-4-[4-hydroxy-3-[sulfoxy]phenyl]-L-threonyl-3-hydroxyglutaminyl-3-
 hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt,
 (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-91-2 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-[(octyloxy)carbonyl]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[(4-hydroxy-3-(sulfoxy)phenyl)-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6S,7R,8L)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-92-3 CAPLUS
 CN L-Proline, N2-[4-[(7-carboxyheptyl)oxy]benzoyl]-(4R,5R)-4,5-dihydroxy-L-
 ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-
 (sulfamoyl)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-,
 cyclic (6. f.w.d.s.w.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-
 (SCI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-93-4 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[[4'-(pentyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithine]-4-[(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-94-5 CAPLUS
 CN Pneumocandin A0, 1-[N2-[[4'-(hexyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-
 (4R,5R)-4,5-dihydroxy-L-ornithine]-4-[(1S)-4-hydroxy-4-[(4-hydroxy-3-
 (sulfoxy)phenyl]-L-threonine)]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-95-6 CAPLUS
 CN L-Proline, N2-[[4'-(2-hexenyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic [6.fwdarw.1]-peptide, monosodium salt, [1(E),6(2.alpha.,3.beta.,4.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1 A




PAGE 2-A




● Na

RN	152686-96-7	CAPLUS
CN	L-Proline, N2-[4,4'-(5-hexenyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-(4R,5R)- 4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy- 4,4'-dihydroxy-3-(sulfoxy)phenyl-L-threonyl-3-hydroxyglutaminyl-3-hydroxy- 4-methyl-, cyclic (6,6fdaarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




● Na

RN CN 152868-97-8 CAPLUS
L-Proline, N2-[1-(1-{(3,5-dimethyl-2,4-hexadienyl)oxy}{1,1'-bisphenyl}-4-
ylcarbonyl)-4(R,S)-4,5-dihydroxy-L-threonine-L-threonine-3-
ylcarbonyl)-4(S,R)-4,5-dihydroxy-3(sulfooxylphenyl)-L-threonine-3-
prolyl-(S)-4-hydroxy-4-[4-hydroxy-3(sulfooxylphenyl)-L-threonine-3-
hydroxylglutaminyl]-3-hydroxy-4-methyl-, cyclic (6.fwdarw.l)-peptide,
monosodium salt, [1E],6(2.alpha.,3.beta.,4.beta.)]- (9CI) (CA INDEX
NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 152868-98-9 CAPLUS
 CN L-Proline, N2-([4'-([3,7-dimethyl-2,6-octadienyl]oxy)[1,1'-biphenyl]-4-yl]carbonyl)-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (8.fwdarw.1)-peptide, monosodium salt, [1(E),6(2.alpha.,3.beta.,4.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN	152868-99-0	CAPLUS
CN	L-Proline, (4R,5R)-4,5-dihydroxy-N-2-[(4'-[(7-hydroxyheptyloxy)[1,1'-biphenyl]-4-yl]carbonyl)-L-ornithinyl-L-threoninyl-trans-4-hydroxy-L-prolyl]-5)-4-hydroxy-4-(4-hydroxy-3-(sulfoxy)phenyl)-L-threoninyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-1 (9CI) [CA INDEX NAME]	

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr 118 10

L18 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2000 ACS

AN 1993:213544 CAPLUS

DN 118:213544

TI Pharmaceutical composition against *Pneumocystis carinii*

IN Furuta, Takahisa; Iwamoto, Toshiro; Fujie, Akihiko; Witta, Kumiko; Tsurumi, Yasuhisa; Shigematsu, Nobuharu; Kasahara, Chiyoishi; Hino, Motohiro; Okuhara, Masakuni

FA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Eur. Pat. Appl., 69 pp.


CODEN: EPXXDW

DT Patent

LA English

FRN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 486011	A2	19920520	EP 1991-119421	19911114
	EP 486011	A3	19920715		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05000966	A2	19930108	JP 1991-354117	19911115
	US 1638	H1	19970304	US 1994-311434	19940926
PRAI	US 1990-614125		19901116		
	GB 1990-27152		19901214		
	GB 1991-1552		19910124		
	GB 1991-6822		19910402		
	US 1990-610759		19901108		
	US 1991-791926		19911115		
OS	MARPAT 118:213544				
GI					



I

AB FR 901379 derivs. I (R1, R2 = H, acyl; R3 = H, OH, O3SOH; R4 = H, carbamoyl; R5, R6 = H, OH) were prepd. Thus, FR 901379 [I, R1 = CO(CH2)14Me, R2 = H, R3 = O3SOH, R4 = CONH2, R5, R6 = OH, II] was isolated from a culture of *Coleophoma* sp. F-11899 and deacylated with Actinoplanes utahensis to give II [R1 = H]. Acylation of II (R1 = H) with 2,4,5-trichloro-6-(2-oxo-2-(2,4,5-trichlorophenyl)ethyl)-4-pyridylcarbamate gave II [R1 = COC6H4O(CH2)7Me-4] which at 2 mg/day i.p. in rats showed significant inhibition of *P. carinii* pneumocysts.

IT 144371-85-7B 144371-87-9P


RL: BAC (Biological activity or effector, except adverse); SEN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

SEARCHED BY SUSAN HANLEY 305-4053


Page 102

(prepn. and bactericidal activity of)
 144371-85-7 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-
 ornithine]-4-[(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-
 , monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 144371-87-9 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-
 ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-
 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 141518-19-6P 141518-20-9P 141518-21-0P
 141518-22-1P 141518-23-2P 141518-24-3P
 141518-34-5P 141518-35-6P 141518-36-7P
 141518-53-8P 141518-54-9P 141537-12-4P

144313-04-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

RN 141518-19-6 CAPLUS

CN L-Proline, N2-[4-(1,1-dimethylethyl)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.7,14,11)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN	141518-20-9	CAPLUS
CN	L-Proline, N2-(4-[(2-butoxyethoxy)benzoyl]-[4R,5R]-4,5-dihydroxy-L-ornithyl-1-phenyl)-trans-4-hydroxy-3-prolyl-(S)-4-hydroxy-3-[(sulfoxyphenyl)-L-threonyl-3-hydroxyglutaminyl]-3-hydroxy-4-methyl-, cyclic [6.fwdarw.1]-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.-1.9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




● Na

RN 141518-21-0 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-(4-phenylbutoxy)benzoyl]-L-ornithyl-
 L-threonyl-trans-4-hydroxy-L-prolyl-[S]-4-hydroxy-4-(4-hydroxy-3-
 [sulfoxy]phenyl)-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-
 cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-22-1 CAPLUS
 CN L-Proline, N2-[2-carboxy-4-(octyloxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-23-2 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[3-methoxy-4-(octyloxy)benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-24-3 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[(2,3,5,6-tetrafluoro-4-
 [(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy]benzoyl)-L-
 ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-
 (sulfoxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-,
 cyclic {6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-
 (9CI) {CA INDEX NAME}

PAGE 1-A




PAGE 2-A



● Na

RN 141518-34-5 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-(4-octylbenzoyl)-L-ornithyl-L-threonyl-
 trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-
 threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic
 (6.fwdar.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-35-6 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-[4-(octyloxy)phenoxy]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-36-7 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt,
 (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-53-8 CAPLUS
 CN Pneumocandin A0, 1-[N2-[[4'-(heptyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-
 (4R,5R)-4,5-dihydroxy-L-ornithine]-4-[(S)-4-hydroxy-4-[4-hydroxy-3-
 (sulfoxy)phenyl]-L-threonine]-, monosodium salt [9CI] (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN	141518-54-9	CAPLUS
CN	L-Proline, N2-[4-[(4-(hexyloxy)phenoxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl]-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-9-cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) [CA INDEX NAME]	

PAGE 1-A




PAGE 2-A




● Na

RN 141537-12-4 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[2,3,5,6-tetrafluoro-4-
 [(2,2,3,3,4,4,5,5-octafluoropentyl)oxy]benzoyl]-L-ornithyl-L-threonyl-
 trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-
 threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic
 (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● Na

RN 144313-04-2 CAPLUS
 CN L-Proline, N2-benzoyl-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxy-L-glutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr 118 11

L18 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2000 ACS

AN 1992:449262 CAPLUS

DN 117:49262

TI Preparation of cyclic peptide (echinosandin B) antibiotics

IN Toshiro, Iwamoto; Akihiko, Fujie; Kumiko, Nitta; Yasuhisa, Tsurumi;

Nobuharu, Shigematsu; Chiyoishi, Kasahara; Motohiro, Hino; Masakuni,

Okuhara; Kazuo, Sakane; et al.

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Eur. Pat. Appl., 69 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 462531	A2	19911227	EP 1991-109856	19910615
	EP 462531	A3	19921104		
	EP 462531	B1	19961002		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FI 9102873	A	19911219	FI 1991-2873	19910614
	IL 98506	A1	19960912	IL 1991-98506	19910614
	EP 729974	A1	19960904	EP 1995-117638	19910615
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 143671	E	19961015	AT 1991-109856	19910615
	ES 2093658	T3	19970101	ES 1991-109856	19910615
	NO 9102347	A	19911219	NO 1991-2347	19910617
	CA 2044746	AA	19911219	CA 1991-2044746	19910617
	AU 9178435	A1	19920116	AU 1991-78435	19910617
	AU 651347	B2	19940721		
	HU 58108	A2	19920128	HU 1991-2014	19910617
	US 5376634	A	19941227	US 1991-715961	19910617
	CN 1059729	A	19920325	CN 1991-104847	19910618
	CN 1040541	B	19981104		
	ZA 9104677	A	19920429	ZA 1991-4677	19910618
	JP 04352799	A2	19921207	JP 1991-245284	19910618
	US 1638	H1	19970304	US 1994-311434	19940926
PRAI	GB 1990-13558		19900618		
	GB 1990-23666		19901031		
	GB 1991-1552		19910124		
	US 1990-610759		19901108		
	US 1990-614125		19901116		
	GB 1990-27152		19901214		
	GB 1991-6822		19910402		
	EP 1991-109856		19910615		
	US 1991-791926		19911115		
OS	MARPAT 117:49262				
GI					



I

AB Title compds. (I; R1 = H, acyl; R2 = OH, acyloxy; R3 = H, HOSO2O; R4 = H, carbamoyl; with provisos that 1) R2 = acyloxy when R3 = H, and 2) R1 = .noteq. palmitoyl when R2 = OH, R3 = HOSO2O, R4 = carbamoyl), were prepd. Thus, antibiotic FR901379 (I; R1 = Co(CH2)14Me, R2 = OH, R3 = OSO2Na, R4 = CONH2) (prepn. given) was fermented with *Actinoplanes utahensis* IFO-13244 to give N-deacylation and the product was acylated with 2,4,5-trichlorophenyl 4-octyloxybenzoate (prepn. given) to give I (R1 = COC6H4[O(CH2)7Me]-4, R2 = OH, R3 = OSO2ONa, R4 = CONH2) (II). II had IC50 = 0.31 (no units) against *Candida albicans* FP578. II at 500 mg/kg i.v. in mice was nontoxic.

IT 141518-07-2P 141518-19-6P 141518-20-9P
141518-21-0P 141518-22-1P 141518-23-2P
141518-24-3P 141518-34-5P 141518-35-6P
141518-36-7P 141518-53-8P 141518-54-9P
141537-12-4P


RI: BAC (Biological activity or effector, except adverse); SEN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as antibiotic)

RN 141518-07-2 CAPLUS

RN 141518-19-6 CAPLUS

CN L-Proline, N2-[4-(1,1-dimethylethylbenzoyl)-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(4-hydroxy-3-(sulfoxy)phenyl)-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-20-9 CAPLUS
 CN L-Proline, N2-[4-(2-butoxyethoxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-[S]-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-21-0 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-(4-phenylbutoxy)benzoyl]-L-ornithyl-
 L-threonyl-(trans-4-hydroxy-L-prolyl)-(S)-4-hydroxy-4-(4-hydroxy-3-
 (sulfamoyl)phenyl)-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-
 cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-22-1 CAPLUS
 CN L-Proline, N2-[2-carboxy-4-(octyloxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdar.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) [CA INDEX NAME]

PAGE 1-A




PAGE 2-A




● Na

RN 141518-23-2 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[3-methoxy-4-(octyloxy)benzoyl]-L-ornithinyl-L-threoninyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(4-hydroxy-3-(sulfoxy)phenyl)-L-threoninyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic [6.fwdarw.1]-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Na


RN 141518-24-3 CAPLUS

CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[2,3,5,6-tetrafluoro-4-
 [(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy]benzoyl]-L-
 ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-
 (sulfoxy)phenyl]-L-threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-,
 cyclic (6.fwdarw.1)-peptide, monosodium salt, [2.alpha.,3.beta.,4.beta.)-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● Na

RN 141518-34-5 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-(4-octylbenzoyl)-L-ornithyl-L-threonyl-
 trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-
 threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic
 (6S,4R,2R,1R)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 141518-35-6 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-(4-(octyloxy)phenoxy)benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(4-hydroxy-3-(sulfoxy)phenyl)-L-threonyl-3-hydroxyglutamyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Na

RN 141518-36-7 CAPLUS
 CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.6wdaew.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)


SEARCHED BY SUSAN HANLEY 305-4053

Page 127

PAGE 1-A




PAGE 2-A




● Na

RN 141518-53-8 CAPLUS
 CN Pneumocandin A0, 1-[N2-[[4'-(heptyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-
 (4R,5R)-4,5-dihydroxy-L-orithine]-4-[[S]-4-hydroxy-4-[4-hydroxy-3-
 (sulfoxy)phenyl]-L-threonine]-, monosodium salt [9CI] (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN	141518-54-9	CAPLUS
CN	L-Proline, N2-[4-[(4-hexyloxy)phenoxy]benzoyl-(4R,5R)-4,5-dihydroxy-L-ornithinyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonyl-3-hydroxyglutaminyl]-3-hydroxy-4-methyl-, (cyclic) (6.fwdarw.)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




● Na

CC	141537-12-4	CAPLUS
EN	L-Proline, (4R,5R)-4,5-dihydroxy-N2-[2,3,5,6-tetrafluoro-4-[(2,2,3,4,4,5,5-octafluoropentyl)oxy]benzoyl]-L-ornithyl-L-threonine-L-trans-4-hydroxy-L-poly(L)-(8)-4-hydroxy-4-(4-hydroxy-3-(sulfoxyphenyl)-L-threonine)-3-hydroxyglutaminyl-L-3-hydroxy-4-methyl-, cyclic	
FR	(6.6edawr, L)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.,4).- (9CR)	
CA	CA_INDEX_NAME	

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs histcr 118 1

L18 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2000 ACS
 AN 2000:11442 CAPLUS
 DN 132:148942
 TI In vitro activities of a new lipopeptide antifungal agent, FK463, against
 a variety of clinically important fungi
 AU Tawara, Shuichi; Ikeda, Fumiaki; Maki, Katsuyuki; Morishita, Yoshihiko;
 Osumi, Kazumi; Teratani, Noriko; Goto, Toshio; Tomishima, Masaki; Ohki,
 Hidenori; Yamada, Akira; Kawabata, Koji; Takasugi, Hisashi; Sakane, Kazuo;
 Tanaka, Hirokazu; Matsumoto, Fumio; Kuwahara, Shogo
 CS Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co.,
 Ltd., Osaka, 532-8514, Japan
 SO Antimicrob. Agents Chemother. (2000), 44(1), 57-62
 CODEN: AMACQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English
 AB The in vitro antifungal activity and spectrum of FK463 were compared with
 those of amphotericin B, fluconazole, and itraconazole by using a broth
 microdilution method specified by National Committee for Clin. Lab. Stds.
 document M27-A (National Committee for Clin. Lab. Stds., Wayne, Pa.,
 1997). FK463 exhibited broad-spectrum activity against clin. important
 pathogens including *Candida* species (MIC range, 0.0039 to 2 .mu.g/mL) and
Aspergillus species (MIC range, 0.0039 to 0.0313 .mu.g/mL), and its MICs
 for such fungi were lower than those of the other antifungal agents
 tested. FK463 was also potentially active against azole-resistant *Candida*
 albicans as well as azole-susceptible strains, and there was no
 cross-resistance with azoles. FK463 showed fungicidal activity against *C.*
 albicans, i.e., a 99% redn. in viability after a 24-h exposure at concns.
 above 0.0156 .mu.g/mL. The min. fungicidal concn. (MFC) assays indicated
 that FK463 was fungicidal against most isolates of *Candida* species. In
 contrast, the MFCs of FK463 for *A. fumigatus* isolates were much higher
 than the MICs, indicating that its action is fungistatic against this
 species. FK463 had no activity against *Cryptococcus neoformans*,
Trichosporon species, or *Fusarium solani*. Neither the test medium (kind
 and pH) nor the inoculum size greatly affected the MICs of FK463, while
 the addn. of 4% human serum albumin increased the MICs for *Candida* species
 and *A. fumigatus* more than 32 times. Results from preclin. in vitro
 evaluations performed thus far indicate that FK463 should be a potent
 parenteral antifungal agent.
 IT 208538-73-2, FK463
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in vitro activities of the new lipopeptide antifungal agent FK463
 against a variety of clin. important fungi)
 RN 208538-73-2 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentoxyl)phenyl]-3-
 isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-
 (sulfoxy)phenyl]-L-threonine], monosodium salt [9CI] (CA INDEX NAME)

=> d bib abs hitstr 118 2

L18 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:511176 CAPLUS
 DW 131:144853
 TI Cyclic hexapeptides having antimicrobial activity
 IN Ohki, Hidenori; Murano, Kenji; Tojo, Takashi; Shiraishi, Nobuyuki;
 Matsuya, Takahiro; Matsuda, Hiroshi; Mizuno, Hiroaki; Barrett, David;
 Matsuda, Keiji; Kawabata, Kohji
 FA Fujisawa Pharmaceutical Co., Ltd., Japan; et al.
 SO ECT Int. Appl., 470 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9940108	A1	19990812	WO 1999-JP538	19990205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LV, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9922398	A1	19990823	AU 1999-22998	19990205
FRAI AU 1998-1728		19980209		
AU 1998-3138		19980423		
WO 1999-JP538		19990205		
OS MARPAT 131:144853				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Polypeptides I [R1 = H, (un)substituted arylaminoalkanoyle, aroyl, arylalkanoyle, or alkanoyl, amino protective group, heptylnaphthoyle, hexylnaphthoyle; R2 = H, OH; R3 = OH, hydroxysulfonyloxy, alkoxy; R4 = OH, alkoxy] or their salts were prepd. as antimicrobial activities (esp., antifungal activities). Thus, cyclic peptide II, prepd. via N-acylation using 4-[5-[4-(6-methoxyhexyloxy)phenyl]-1,3,4-chladiazol-2-yl]benzoic acid benzotriazol-1-yl ester, showed MIC 0.0625 .mu.g/mL for inhibition of *Candida albicans*.

IT 235114-33-7P
 R1: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cyclic hexapeptides having antimicrobial activity)

RN 235114-33-7 CAPLUS


CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-, compd. with N-ethyl-N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 235114-32-6

CMF C56 H71 N9 O23 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 7087-68-5

CMF C8 H19 N



IT 235114-36-0 235114-38-2 235114-39-3
235114-41-7 235114-42-8 235114-45-1
235114-46-2 235114-48-4

RL: RCT (Reactant)

(cyclic hexapeptides having antimicrobial activity)

RN 235114-36-0 CAPLUS


CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(1-piperidinyl)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-, monosodium salt

SEARCHED BY SUSAN HANLEY 305-4053


Page 4

(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 235114-38-2 CAPLUS
 CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[4-(octyloxy)phenyl]-1-piperazinyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)